Executive Director, State Government Affairs

About Stoke:

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study.

Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study.

Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit

The Executive Director, State Government Affairs will lead Stoke Therapeutics’ state-level government affairs strategy across priority U.S. states, advancing policy environments that support people living with Dravet syndrome and other severe genetic diseases, access to innovative RNA medicines, and potential future access to zorevunersen, if approved. The role will focus on state legislative, regulatory, Medicaid, rare disease, genetic testing, and access policies.

Reporting to the Vice President, Patient Advocacy and Policy, this leader will serve as a senior strategic partner across Patient Advocacy, Policy, Medical Affairs, Market Access, Regulatory, Compliance, and Communications. The Executive Director will anticipate external risks and opportunities, shape policy solutions, and ensure that state engagement reflects patient and caregiver experience while aligning with Stoke’s business objectives.

• Develop and execute a comprehensive state government affairs strategy and priority-state plans aligned with Stoke’s patient advocacy, policy, commercial, medical, regulatory, market access, compliance, and communications objectives.
• Monitor, analyze, and influence state legislative, executive, regulatory, and political developments affecting rare disease, Dravet syndrome, genetic testing, pediatric neurology, Medicaid, commercial insurance, and access to innovative therapies; provide timely, actionable guidance on risks and opportunities.
• Advance policy readiness for potential future access to zorevunersen, if approved, including coverage pathways, medical and pharmacy benefit considerations, utilization management, site of care, continuity of coverage, and recognition of disease-modifying value.
• Shape Medicaid and pediatric rare disease policy, including prior authorization, medical necessity criteria,…